{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:21:16Z","timestamp":1793146876545,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T23:51:07Z","timestamp":1732578667000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Elexacaftor\/tezacaftor\/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-2799","authenticated-orcid":false,"given":"CJ","family":"Bathgate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-910X","authenticated-orcid":false,"given":"DA","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9811","authenticated-orcid":false,"given":"EM","family":"Tillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-5436","authenticated-orcid":false,"given":"RS","family":"Everhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-9070","authenticated-orcid":false,"given":"LR","family":"Reznikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FF","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Raffensperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Traver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-3512","authenticated-orcid":false,"given":"KA","family":"Riekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-9650","authenticated-orcid":false,"given":"SW","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-4031","authenticated-orcid":false,"given":"AM","family":"Georgiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.006_bib0002","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcf.2020.07.020","article-title":"Decreased survival in cystic fibrosis patients with a positive screen for depression","volume":"20","author":"Schechter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0003","article-title":"Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","author":"Van Citters","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2018.11.010","article-title":"Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community","volume":"18","author":"Hollin","year":"2019","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.11.006_bib0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40900-021-00328-4","article-title":"Development and evaluation of a virtual patient-centered outcomes research training program for the cystic fibrosis community","volume":"7","author":"Godfrey","year":"2021","journal-title":"Res Involv Engagem"},{"key":"10.1016\/j.jcf.2024.11.006_bib0006","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1172\/JCI118080","article-title":"Expression and localization of the cystic fibrosis transmembrane conductance regulator mRNA and its protein in rat brain","volume":"96","author":"Mulberg","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.11.006_bib0007","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1152\/jn.00511.2017","article-title":"A role for the cystic fibrosis transmembrane conductance regulator in the nitric oxide-dependent release of Cl(-) from acidic organelles in amacrine cells","volume":"118","author":"Krishnan","year":"2017","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.11.006_bib0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12967-021-03092-x","article-title":"Regional brain tissue changes in patients with cystic fibrosis","volume":"19","author":"Roy","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0010","doi-asserted-by":"crossref","first-page":"16278","DOI":"10.1038\/s41598-020-73298-4","article-title":"Alleviation of depression-like behavior in a cystic fibrosis mouse model by Hdac6 depletion","volume":"10","author":"Corey","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2024.11.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2024.11.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104384","article-title":"Restoring myocardial infarction-induced long-term memory impairment by targeting the cystic fibrosis transmembrane regulator","volume":"86","author":"Vanherle","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jcf.2024.11.006_bib0013","unstructured":"European Medicines Agency. Assessment report: Kaftrio. Amsterdam, The Netherlands.2020."},{"key":"10.1016\/j.jcf.2024.11.006_bib0014","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Schneider-Futschik EK. Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcf.2023.04.012","article-title":"The combination elexacaftor\/tezacaftor\/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner","volume":"22","author":"Liessi","year":"2023","journal-title":"J Cystic Fibros:"},{"key":"10.1016\/j.jcf.2024.11.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.05.004","article-title":"Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)","author":"Ciobanu","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0017","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0018","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.11.006_bib0019","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2024.11.006_bib0022","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Multi-discipline review, elexacaftor\/tezacaftor\/ivacaftor. 2019."},{"issue":"2","key":"10.1016\/j.jcf.2024.11.006_bib0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.006_bib0024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0027","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Sermet-Gaudelus","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.11.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2024.102301","article-title":"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens","volume":"86","author":"Rose","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.006_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2024.11.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27100","article-title":"Mental health, sleep, and respiratory health after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis","author":"Pham","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.006_bib0031","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2024.11.006_bib0032","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ppul.26116","article-title":"Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis","volume":"57","author":"Lyman","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0033","doi-asserted-by":"crossref","first-page":"e20110","DOI":"10.1016\/j.heliyon.2023.e20110","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis","volume":"9","author":"Allgood","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jcf.2024.11.006_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0035","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ppul.26260","article-title":"A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis","volume":"58","author":"Sakon","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0036","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2024.11.006_bib0037","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and Psychopathology in Cystic Fibrosis: a Case Report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jcf.2024.11.006_bib0038","article-title":"A Case of Elexacaftor\/Tezacaftor\/Ivacaftor-Induced Depressive Symptoms and Suicidal Thoughts","volume":"26","author":"Godier","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.jcf.2024.11.006_bib0039","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.11.006_bib0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor Treatment and Depression-related Events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0042","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/alr.23209","article-title":"Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy","volume":"13","author":"Tervo","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0043","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jcf.2024.11.006_bib0044","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcf.2022.11.006","article-title":"Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis","volume":"22","author":"Kass","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcf.2023.05.005","article-title":"Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Meltzer","year":"2024","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0046","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0047","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1159\/000524773","article-title":"Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis","volume":"101","author":"Welsner","year":"2022","journal-title":"Respiration"},{"key":"10.1016\/j.jcf.2024.11.006_bib0048","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/genes14020449","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease","volume":"14","author":"Giallongo","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcf.2024.11.006_bib0049","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0050","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","volume":"280","author":"Bode","year":"2023","journal-title":"Eur Arch oto-rhino-laryngol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0051","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: Healthcare providers' observations across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.11.006_bib0052","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.jcf.2024.11.006_bib0053","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jcf.2017.11.021","article-title":"Quality of life and mood in children with cystic fibrosis: associations with sleep quality","volume":"17","author":"Vandeleur","year":"2018","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0054","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jcf.2024.03.005","article-title":"Symptoms and quality of life in adults with cystic fibrosis: a cross-sectional analysis of the InSPIRe:CF trial","volume":"23","author":"Smirnova","year":"2024","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0055","first-page":"82","article-title":"New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"29","author":"Duehlmeyer","year":"2024","journal-title":"J Pediatric Pharmacol Therapeut"},{"key":"10.1016\/j.jcf.2024.11.006_bib0056","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0057","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0058","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0059","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1164\/rccm.202311-2159ED","article-title":"Questions and Answers? Depression Symptoms Associated with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment for Cystic Fibrosis","volume":"209","author":"Lee","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/tbm\/ibz165","article-title":"How intensive longitudinal data can stimulate advances in health behavior maintenance theories and interventions","volume":"11","author":"Dunton","year":"2021","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.jcf.2024.11.006_bib0061","doi-asserted-by":"crossref","first-page":"e29812","DOI":"10.2196\/29812","article-title":"Analyzing Patient Trajectories With Artificial Intelligence","volume":"23","author":"Allam","year":"2021","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jcf.2024.11.006_bib0062","first-page":"856","article-title":"Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom","volume":"6","author":"Lee","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.jcf.2024.11.006_bib0063","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor\/Tezacaftor\/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis. 2024."},{"key":"10.1016\/j.jcf.2024.11.006_bib0064","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1569-1993(24)00962-7","article-title":"Vanzacaftor\/tezacaftor\/deutivacaftor in adolescents and adults with cystic fibrosis: results from two randomized, active-controlled phase 3 trials","volume":"23","author":"Keating","year":"2024","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.11.006_bib0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1164\/rccm.202010-3943ST","article-title":"Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement","volume":"203","author":"Gershon","year":"2021","journal-title":"Am J Respirat Critic Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:37:17Z","timestamp":1777333037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1569199324018149"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}